New Delhi, June 24, 2025 – Danish pharmaceutical giant Novo Nordisk has officially launched its once‑weekly injectable weight‑loss drug Wegovy (semaglutide 2.4 mg) in India, marking a significant milestone in the country’s fight against obesity and related cardiometabolic diseases economictimes.indiatimes.com+15reuters.com+15economictimes.indiatimes.com+15.
Table of Contents
Novo Nordisk : A Strategic Market Entry
Wegovy joins India’s growing arsenal of GLP‑1 receptor agonists aimed at chronic weight management. It arrives nearly three months after Eli Lilly introduced its dual‐agonist Mounjaro (tirzepatide), igniting a high‑stakes rivalry in a rapidly expanding market m.economictimes.com+11reuters.com+11business-standard.com+11.
Novo Nordisk is positioning Wegovy not just as a weight‑loss therapy but as a tool to reduce cardiovascular risk—a move it describes as its “20‑20 strategy”: 20 % body‑weight reduction alongside a 20 % drop in major adverse cardiovascular events m.economictimes.com+1timesofindia.indiatimes.com+1.
Pricing and Accessibility
Wegovy will be sold across India in five dosage strengths—0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg—using a user‑friendly pen device designed for home use indiatoday.in+15reuters.com+15hindustantimes.com+15. Pricing is tiered:
- 0.25 mg, 0.5 mg, 1 mg pens: ₹17,345/month (≈₹4,336/week)
- 1.7 mg pens: ₹24,280/month
- 2.4 mg pens: ₹26,015/month economictimes.indiatimes.comm.economictimes.com+4indianexpress.com+4m.economictimes.com+4.
These rates closely mirror Mounjaro’s, which is priced between ₹14,000–17,500 per month depending on dosage omniekonomi.se+8indianexpress.com+8reuters.com+8. Importantly, Novo Nordisk has assured that the rollout will be free from supply constraints — a critical issue globally — emphasizing stable supply across both urban and rural areas en.wikipedia.org+11reuters.com+11tradingview.com+11.
Clinical Evidence & Positioning
Wegovy leverages the clinical legacy of semaglutide, the GLP‑1 analogue that underpins Ozempic and Rybelsus. Studies show:
- ~15% average weight loss at week 68 compared to placebo indiatoday.in+15en.wikipedia.org+15indianexpress.com+15.
- In India, one in three users lost ≥20% body weight dawn.com+1indianexpress.com+1.
- Cardiovascular benefits include approximately 20% risk reduction in major adverse events such as heart attack and stroke hindustantimes.com+2expresshealthcare.in+2indianexpress.com+2.
Brazil to US clinical trials involving ~17,600 participants demonstrated a significant mortality and morbidity benefit when semaglutide was combined with standard care . The company further cites data from India‑specific trials involving over 3,500 participants .
Competitive Dynamics & Future Prospects
India’s obesity drug market is witnessing a fierce competition. Mounjaro has seen early adoption, with over 81,000 units sold in weeks and revenues nearing ₹24 crore—boosting its standing as a rapid first mover indiatoday.in+5m.economictimes.com+5economictimes.indiatimes.com+5. Clinical trials indicate tirzepatide may produce slightly higher weight‑loss (~23% average), but Wegovy’s established evidence base and cardiovascular data provide a compelling differentiator economictimes.indiatimes.com+5m.economictimes.com+5business-standard.com+5.
Novo Nordisk has ambitious aims: targeting ₹8,600 crore (~$1 billion) in Indian Wegovy sales over the next 5–7 years m.economictimes.com+1economictimes.indiatimes.com+1. Their strategy includes broad market reach, aggressive pricing, and caregiver/prescriber engagement programs emphasizing cardiometabolic benefits m.economictimes.com.
Patent Expiry & Generic Threat
Semaglutide’s patent in India expires in 2026. Local generics manufacturers—such as Sun Pharma, Cipla, Dr. Reddy’s, and Lupin—are already preparing for market entry economictimes.indiatimes.com+3m.economictimes.com+3dawn.com+3. Analysts predict generic versions could slash prices by 60–90%, dramatically expanding access but compressing margins for branded versions reuters.com+1m.economictimes.com+1. Legal action is already underway: Novo is suing certain generics providers over alleged patent infringement, with a Delhi High Court injunction in effect until at least August 19, 2025 economictimes.indiatimes.com.
Tackling India’s Obesity Burden
India faces a major public‑health challenge: 24% of women and 23% of men aged 15–49 were overweight or obese between 2019–21, up significantly from 2015–16 dawn.com+1reuters.com+1. Obesity is linked to over 200 diseases, including type‑2 diabetes, cardiovascular disease, and certain cancers expresshealthcare.in+1hindustantimes.com+1. In this context, the availability of advanced therapies like Wegovy could mark a turning point—if accessibility and cost challenges are addressed.
The Road Ahead
The next 18 months in India’s obesity‑drug market will be pivotal. Both Wegovy and Mounjaro will compete intensely in the branded space through mid‑2026. Afterwards, the entry of generics may trigger a market transformation—driving volume, slashing prices, and making these life‑changing treatments more accessible m.economictimes.com.
Novo Nordisk’s Indian LD, Vikrant Shrotriya, said:
“Obesity is not just a personal health concern — it is a chronic disease and a national epidemic that India cannot afford to ignore…” indiatoday.in+6indianexpress.com+6hindustantimes.com+6
Whether Wegovy fulfills its potential depends on affordability, physician engagement, and sustained supply—as generics loom on the horizon. Its launch, however, underscores a broader global shift toward pharmacological solutions for obesity and cardiometabolic health.
Also Read :https://latestindiannews.com/daily-routine-plan-for-every-professionals/